Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India".
Press Release Mar 18 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus will manufacture the product, while Torrent will market it under its brand name, leveraging its strong presence in chronic therapies. Zydus will market the product under its own brand names, enhancing patient convenience with a reusable pen device.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 17 2026
- Press Release Mar 16 2026
- Press Release Mar 14 2026
- Press Release Mar 13 2026
- Press Release Mar 12 2026
Later from Zydus Lifesciences
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 19 2026
- Zydus Lifesciences Limited Press Release Mar 21 2026
- Press Release Apr 08 2026
- Press Release Apr 16 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences